semaglutide cardiac protection FLOW Analysis: Delivers Consistent Kidney Benefit in T2D/CKD Across CVD Status Semaglutide approved for cardiovascular disease

These results held across diverse populations, confirming that the 4 to 8 week window is realistic for most patients beginning their GLP-1 therapy

Hyaluronic acid is often hailed to have the ability to reverse or sometimes completely stop dryness

No, semaglutide does not automatically require lifelong use

3.2% of participants in the semaglutide group discontinued their treatment due to side effects, compared to 12.6% with liraglutide

Additional data show that liraglutide reduces several markers of cardiovascular risk, such as body weight, A1C levels, Systolic BP, C-reactive protein, type 2 natriuretic peptide, and PAI-1 [108, 109]

doi: 10.1136/jnnp-2017-316011 126 YongHYFYongVW